Department of Rheumatic and Immunologic Diseases, Orthopaedic & Rheumatologic Institute, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Cleve Clin J Med. 2020 Jun 30;87(7):389-393. doi: 10.3949/ccjm.87a.ccc008.
Knowledge about the pathobiology of SARS-CoV-2 as it interacts with immune defenses is limited. SARS-CoV-2 is spread by droplets that come into contact with mucous membranes. COVID-19 is characterized by 2 or 3 stages: most patients who recover experience 2 stages of illness commencing with an asymptomatic or paucisymptomatic incubation period, followed by a nonsevere symptomatic illness lasting for several weeks, occurring in about 80% of those infected. In the remainder, a third phase marked by a severe respiratory illness, often accompanied by multisystem dysfunction, coagulopathy, and shock is observed. This phase of the illness is characterized by hypercytokinemic inflammation and is often referred to as "cytokine storm." While the immunopathogenesis remains unclear, prospects of treating this severe phase of the illness with immunotherapy are evolving, with some treatments showing promise.
关于 SARS-CoV-2 与免疫防御相互作用的病理生物学知识有限。SARS-CoV-2 通过飞沫传播,飞沫接触到黏膜。COVID-19 有 2 或 3 个阶段:大多数康复的患者经历 2 个阶段的疾病,首先是无症状或症状轻微的潜伏期,然后是非严重的有症状疾病持续数周,约 80%的感染者会出现这种情况。在其余患者中,观察到第三个阶段,以严重的呼吸道疾病为特征,常伴有多系统功能障碍、凝血功能障碍和休克。这一疾病阶段的特点是细胞因子过度活跃炎症,通常被称为“细胞因子风暴”。虽然免疫发病机制仍不清楚,但用免疫疗法治疗这种严重阶段疾病的前景正在发展,一些治疗方法显示出希望。